Biotech Startup Investment Stays Steady as AI Funding Surges

Crunchbase News reports that while the AI boom has disrupted startup funding patterns, biotech has remained comparatively stable. Global funding to biotech startups has hovered between $36 billion and $40 billion over the past few years, and 2026 is on track to remain close to that range. The takeaway for readers: biotech has not matched AI’s funding frenzy, but it has continued to attract consistent venture investment.

Some of the year’s largest biotech financings went to companies working at the intersection of biotech and AI. Crunchbase data cited in the article says more than $6 billion has gone to AI-focused biotechs so far this year. The largest listed round was a $2.1 billion Series B for London-based Isomorphic Labs, followed by major financings for Earendil Labs and Chai Discovery.

The broader biotech startup pipeline remains heavily weighted toward seed and early-stage rounds, which Crunchbase News says make up more than half of all investment and most rounds. The article notes that later-stage biotechs often pursue public listings after Series B or Series C rounds rather than raising another venture round. Examples cited include Kailera Therapeutics, Kardigan and Latigo Biotherapeutics, all of which went public after relatively recent early-stage financing activity.

Biotech startups also delivered sizable M&A exits in 2026. Per Crunchbase data cited in the article, at least 12 funded companies sold in transactions valued at $1 billion or more, including potential milestone payments. The overall signal: biotech funding and exits are holding up, even if the sector looks more measured than the current AI investment cycle.